0001493152-16-011567.txt : 20160715 0001493152-16-011567.hdr.sgml : 20160715 20160715121538 ACCESSION NUMBER: 0001493152-16-011567 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160715 DATE AS OF CHANGE: 20160715 EFFECTIVENESS DATE: 20160715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SignPath Pharma, Inc. CENTRAL INDEX KEY: 0001455694 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205079533 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-267104 FILM NUMBER: 161769173 BUSINESS ADDRESS: STREET 1: 3477 CORPORATE PARKWAY, SUITE 100 CITY: CENTER VALLEY STATE: PA ZIP: 18034 BUSINESS PHONE: 215-538-9996 MAIL ADDRESS: STREET 1: 3477 CORPORATE PARKWAY, SUITE 100 CITY: CENTER VALLEY STATE: PA ZIP: 18034 D 1 primary_doc.xml X0707 D LIVE 0001455694 SignPath Pharma, Inc. 3477 CORPORATE PARKWAY, SUITE 100 CENTER VALLEY PA PENNSYLVANIA 18034 215-538-9996 DELAWARE None None Corporation true Lawrence D. Helson 3477 Corporate Parkway, Suite 100 Center Valley PA PENNSYLVANIA 18034 Executive Officer Director CEO, CFO and Director Arthur P. Bollon, Ph.D 3477 Corporate Parkway, Suite 100 Center Valley PA PENNSYLVANIA 18034 Director Jack Levine, CPA 3477 Corporate Parkway, Suite 100 Center Valley PA PENNSYLVANIA 18034 Director None Meyers Associates, L.P. 45 Broadway 2nd Floor New York NY NEW YORK 10006 Promoter Kai Larson, JD 3477 Corporate Parkway, Suite 100 Center Valley PA PENNSYLVANIA 18034 Executive Officer Chief Operating Officer and Secretary Pharmaceuticals Decline to Disclose 06b false 2016-03-31 false true true false 100000 Meyers Associates, L.P. 34171 John D. Telfer 1099745 45 BROADWAY 2ND FLOOR NEW YORK NY NEW YORK 10006 All States false 5000000 245000 4755000 true 0 8 650000 0 Meyers Associates, L.P. will receive a 10% commission, warrants to purchase up to 20% of the Units sold and a non-accountable expense allowance equal to 3% of the gross proceeds. 404000 true $200,000 towards the COO's salary, provided, however, $150,000 of his salary is deferred unless and until the Company raises an aggregate of $10,000,000; and $204,000 towards the CEO's salary. false SignPath Pharma, Inc. /s/ Lawrence Helson Lawrence Helson CEO and CFO 2016-07-15